{"id":"quadruple-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen typically combines direct-acting antivirals (DAAs) with different mechanisms of action to inhibit viral protease, polymerase, and NS5A functions, while potentially including an immunomodulatory component. The multi-targeted approach reduces the likelihood of resistance development and improves sustained virological response rates.","oneSentence":"Quadruple therapy combines four antiviral agents to simultaneously target multiple stages of viral replication and host factors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:03:35.728Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Helicobacter_pylori_eradication_protocols","title":"Helicobacter pylori eradication protocols","extract":"Helicobacter pylori eradication protocols is a standard name for all treatment protocols for peptic ulcers and gastritis in the presence of Helicobacter pylori infection. The primary goal of the treatment is not only temporary relief of symptoms but also total elimination of H. pylori infection. Patients with active duodenal or gastric ulcers and those with a prior ulcer history should be tested for H. pylori. Appropriate therapy should be given for eradication. Patients with MALT lymphoma should also be tested and treated for H. pylori since eradication of this infection can induce remission in many patients when the tumor is limited to the stomach. Several consensus conferences, including the Maastricht Consensus Report, recommend testing and treating several other groups of patients but there is limited evidence of benefit. This includes patients diagnosed with gastric adenocarcinoma, patients found to have atrophic gastritis or intestinal metaplasia, as well as first-degree relatives of patients with gastric adenocarcinoma since the relatives themselves are at increased risk of gastric cancer partly due to the intrafamilial transmission of H. pylori. To date, it remains controversial whether to test and treat all patients with functional dyspepsia, gastroesophageal reflux disease, or other non-GI disorders as well as asymptomatic individuals."},"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection"}]},"trialDetails":[{"nctId":"NCT06732245","phase":"PHASE2","title":"Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese","status":"NOT_YET_RECRUITING","sponsor":"Biomed Industries, Inc.","startDate":"2026-08-15","conditions":"Obesity and Overweight","enrollment":224},{"nctId":"NCT06561711","phase":"PHASE4","title":"Optimization of Minocycline for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-21","conditions":"Helicobacter Pylori Infection","enrollment":480},{"nctId":"NCT05403541","phase":"PHASE3","title":"Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2022-06-27","conditions":"Generalized Myasthenia Gravis","enrollment":240},{"nctId":"NCT06977841","phase":"NA","title":"Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2025-06-10","conditions":"Helicobacter Pylori Eradication, Adverse Reaction","enrollment":640},{"nctId":"NCT07482059","phase":"PHASE1, PHASE2","title":"A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-02","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT07179159","phase":"NA","title":"Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial","status":"RECRUITING","sponsor":"Yanqing Li","startDate":"2025-09-09","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":372},{"nctId":"NCT06340334","phase":"NA","title":"Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-03-31","conditions":"Helicobacter Pylori Infection, Tegoprazan, Furazolidone","enrollment":400},{"nctId":"NCT06412588","phase":"NA","title":"Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-06-15","conditions":"Helicobacter Pylori Infection","enrollment":579},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT06943794","phase":"NA","title":"Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Gastric (Stomach) Cancer","enrollment":4824},{"nctId":"NCT07405684","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp First-line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":544},{"nctId":"NCT07405697","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp Rescue Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"Helicobacter Pylori Infection","enrollment":290},{"nctId":"NCT07010744","phase":"NA","title":"Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Akil Al Islam","startDate":"2025-07-01","conditions":"Dyspepsia","enrollment":66},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":"Chemotherapy Effect","enrollment":198},{"nctId":"NCT07358130","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2025-10-21","conditions":"Helicobacter Pylori Infection","enrollment":552},{"nctId":"NCT05647278","phase":"PHASE4","title":"Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)","status":"COMPLETED","sponsor":"Zhang Xiaofeng,MD","startDate":"2023-11-01","conditions":"Helicobacter Pylori Infection","enrollment":370},{"nctId":"NCT07334535","phase":"PHASE4","title":"Isa-VRD in TIE HRMM","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-30","conditions":"Multiple Myeloma","enrollment":117},{"nctId":"NCT04991103","phase":"PHASE2","title":"Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Multiple Myeloma, Amyloidosis","enrollment":40},{"nctId":"NCT07312721","phase":"PHASE4","title":"Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis","status":"COMPLETED","sponsor":"Azfar Farogh","startDate":"2024-01-05","conditions":"Helicobacter Pylori Infection, Chronic Gastritis, Peptic Ulcer Disease","enrollment":752},{"nctId":"NCT07307287","phase":"PHASE2","title":"SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-20","conditions":"SHR-A1811, HER2-Postive Breast Cancer, HR+ Breast Cancer","enrollment":30},{"nctId":"NCT05524571","phase":"PHASE3","title":"Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2023-01-05","conditions":"Thyroid Eye Disease","enrollment":100},{"nctId":"NCT07285096","phase":"","title":"P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Yueyue Li","startDate":"2025-12-16","conditions":"Helicobacter Pylori Infection","enrollment":1730},{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT05517421","phase":"PHASE3","title":"Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease","status":"COMPLETED","sponsor":"Immunovant Sciences GmbH","startDate":"2022-11-23","conditions":"Thyroid Eye Disease","enrollment":114},{"nctId":"NCT07139366","phase":"PHASE4","title":"Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2025-10-28","conditions":"Gastritis, Dyspepsia, Helicobacter Pylori Infection","enrollment":1248},{"nctId":"NCT07260006","phase":"NA","title":"Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease","status":"RECRUITING","sponsor":"Can Tho University of Medicine and Pharmacy","startDate":"2024-10-01","conditions":"Helicobacter Pylori Infection, Peptic Ulcer","enrollment":80},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT03431688","phase":"NA","title":"Tailored Therapy for Clarithromycin-Resistant H. Pylori","status":"COMPLETED","sponsor":"Kangdong Sacred Heart Hospital","startDate":"2018-10-01","conditions":"Helicobacter Pylori Infection","enrollment":782},{"nctId":"NCT05874544","phase":"PHASE4","title":"Rescue Therapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-16","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT07165444","phase":"NA","title":"Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-09-11","conditions":"Potassium-Competitive Acid Blocker, Proton Pump Inhibitor, Bismuth Based Quadruple Therapy","enrollment":320},{"nctId":"NCT07167511","phase":"","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Yueyue Li","startDate":"2022-01-01","conditions":"Helicobacter Pylori Infection","enrollment":1730},{"nctId":"NCT04332848","phase":"PHASE4","title":"Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-07-28","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT07146594","phase":"PHASE4","title":"Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"Athens Medical Center","startDate":"2025-08-20","conditions":"Helicobacter Pylori Gastritis, Helicobacter Eradication","enrollment":150},{"nctId":"NCT07144657","phase":"PHASE2","title":"Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-01","conditions":"MALT Lymphoma of Stomach","enrollment":40},{"nctId":"NCT07130253","phase":"NA","title":"Efficacy of Vonoprazan-based Rescue Therapy for H. Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-08-18","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":220},{"nctId":"NCT07122024","phase":"PHASE4","title":"Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-02-19","conditions":"Helicobacter Pylori","enrollment":414},{"nctId":"NCT07068607","phase":"PHASE4","title":"Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2025-04-01","conditions":"Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer","enrollment":400},{"nctId":"NCT05870540","phase":"PHASE2","title":"BPL-003 Efficacy and Safety in Treatment Resistant Depression","status":"COMPLETED","sponsor":"Beckley Psytech Limited","startDate":"2023-09-14","conditions":"Treatment Resistant Depression","enrollment":196},{"nctId":"NCT05790525","phase":"PHASE4","title":"Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-11-22","conditions":"Helicobacter Pylori","enrollment":200},{"nctId":"NCT06514274","phase":"PHASE4","title":"Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-09-20","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":558},{"nctId":"NCT06523764","phase":"PHASE4","title":"Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-11-11","conditions":"Helicobacter Pylori Infection Chronic Gastrit","enrollment":208},{"nctId":"NCT06168084","phase":"PHASE4","title":"Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy","status":"COMPLETED","sponsor":"Yongquan Shi","startDate":"2023-06-06","conditions":"Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer","enrollment":688},{"nctId":"NCT05742568","phase":"PHASE4","title":"Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-12-01","conditions":"Gastritis, Dyspepsia, Helicobacter Pylori Infection","enrollment":124},{"nctId":"NCT07012785","phase":"NA","title":"Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2025-06","conditions":"H. Pylori Infection","enrollment":208},{"nctId":"NCT06942559","phase":"NA","title":"Brain-Oscillation Synchronized Stimulation of the DMPFC","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2025-01-29","conditions":"Obsessive Compulsive Disorder (OCD), Treatment Resistant Obsessive Compulsive Disorder","enrollment":48},{"nctId":"NCT04491955","phase":"PHASE2","title":"Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Small Bowel Cancers, Colorectal Cancers","enrollment":32},{"nctId":"NCT03897244","phase":"PHASE4","title":"Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-05-30","conditions":"Helicobacter Pylori Infection","enrollment":603},{"nctId":"NCT05984602","phase":"PHASE1","title":"A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-07-14","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT05572957","phase":"NA","title":"LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-10-14","conditions":"Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block","enrollment":50},{"nctId":"NCT03365609","phase":"NA","title":"A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children","status":"RECRUITING","sponsor":"Ying HUANG","startDate":"2017-09-20","conditions":"Helicobacter Infections","enrollment":1440},{"nctId":"NCT06082323","phase":"PHASE1","title":"A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers","status":"RECRUITING","sponsor":"Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.","startDate":"2024-06-13","conditions":"Healthy Volunteer, Hidradenitis Suppurativa, Atopic Dermatitis","enrollment":127},{"nctId":"NCT06823791","phase":"PHASE1, PHASE2","title":"Furazolidone Quadruple Regimen Eradicate H. Pylori Infection","status":"COMPLETED","sponsor":"Liaocheng People's Hospital","startDate":"2022-08-01","conditions":"Helicobacter Pylori Infection, Eradication","enrollment":493},{"nctId":"NCT06809920","phase":"NA","title":"Analysis of Knee Joint of Patients with Anterior Cruciate Ligament Injury Undergoing Physiotherapy After Two Different Surgical Techniques: a Randomized Clinical Trial.","status":"NOT_YET_RECRUITING","sponsor":"Universidade Estadual de Londrina","startDate":"2025-02-01","conditions":"Anterior Cruciate Ligament (ACL) Tear, Anterior Cruciate Ligament Reconstruction Rehabilitation","enrollment":20},{"nctId":"NCT05534750","phase":"PHASE2","title":"Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-20","conditions":"Tuberculosis, Multidrug Resistant Tuberculosis","enrollment":60},{"nctId":"NCT06777732","phase":"EARLY_PHASE1","title":"The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-03","conditions":"Helicobacter Pylori Infection","enrollment":672},{"nctId":"NCT06760065","phase":"PHASE3","title":"Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-15","conditions":"Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education","enrollment":316},{"nctId":"NCT03640312","phase":"PHASE2","title":"Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-08-30","conditions":"Hypertension","enrollment":62},{"nctId":"NCT05874570","phase":"PHASE4","title":"Doxycycline for Helicobacter Pylori Rescue Treatment","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-06-20","conditions":"Helicobacter Pylori Infection","enrollment":368},{"nctId":"NCT06332599","phase":"","title":"Minocycline for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-03-01","conditions":"Helicobacter Pylori Infection","enrollment":823},{"nctId":"NCT06561698","phase":"PHASE4","title":"High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-21","conditions":"Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT04531059","phase":"PHASE4","title":"Rescue Therapy for Helicobacter Pylori Eradication Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-10-15","conditions":"Helicobacter Pylori Infection","enrollment":368},{"nctId":"NCT02112214","phase":"PHASE3","title":"Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2014-06","conditions":"Gastric Cancer, Helicobacter Pylori Infection","enrollment":5224},{"nctId":"NCT06200779","phase":"PHASE4","title":"Tailored Vs. Empirical Helicobacter Pylori Infection Treatment","status":"NOT_YET_RECRUITING","sponsor":"Manuel Coelho da Rocha","startDate":"2025-09","conditions":"Helicobacter Pylori Infection","enrollment":160},{"nctId":"NCT06731023","phase":"","title":"Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"Xiuli Zuo","startDate":"2025-01-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":30},{"nctId":"NCT00529958","phase":"NA","title":"Comparison of Three Methods for Anterior Cruciate Ligament Reconstruction","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2007-09","conditions":"Anterior Cruciate Ligament Rupture, Deficiency of Anterior Cruciate Ligament, Chronic Instability of Knee","enrollment":330},{"nctId":"NCT06299605","phase":"NA","title":"Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong University","startDate":"2024-11-27","conditions":"Helicobacter Pylori Infection","enrollment":375},{"nctId":"NCT05581199","phase":"PHASE2","title":"To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2022-12-15","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":277},{"nctId":"NCT06687473","phase":"PHASE4","title":"Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-01-01","conditions":"Helicobacter Pylori, Drug Resistance, Multiple, Virulence Factor","enrollment":13},{"nctId":"NCT06687499","phase":"PHASE4","title":"14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-08-22","conditions":"Helicobacter Pylori, Drug Resistance, Multiple","enrollment":46},{"nctId":"NCT05475431","phase":"","title":"Real-world Treatment of H. Pylori Eradication in Patients with Comorbidity","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-05-06","conditions":"Helicobacter Pylori Infection, Comorbidities and Coexisting Conditions, Real-world Outcome","enrollment":1053},{"nctId":"NCT06509139","phase":"PHASE4","title":"Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-07-09","conditions":"Helicobacter Pylori Infection, Sex, Bismuth Quadruple Therapy","enrollment":661},{"nctId":"NCT06676800","phase":"EARLY_PHASE1","title":"Observation Study on the Efficacy of Yiqi Gubiao Pill in the Treatment of Chronic Obstructive Pulmonary Disease Secondary to Active Pulmonary Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Fourth Affiliated Hospital of Xinjiang Medical University","startDate":"2024-11-30","conditions":"Tuberculosis-related Obstructive Pulmonary Disease","enrollment":74},{"nctId":"NCT06591494","phase":"PHASE2, PHASE3","title":"The Efficacy of Quadruple Therapy Containing Sodium Bicarbonate as the Primary Treatment for Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-09-15","conditions":"Helicobacter Pylori Infection","enrollment":855},{"nctId":"NCT06603688","phase":"PHASE4","title":"Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-11-20","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":548},{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT04527055","phase":"PHASE4","title":"The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-05-06","conditions":"Helicobacter Pylori Infection, Dysbiosis, Probiotics","enrollment":312},{"nctId":"NCT04336098","phase":"PHASE1","title":"Study of SRF617 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2020-03-16","conditions":"Advanced Solid Tumor","enrollment":85},{"nctId":"NCT06250634","phase":"NA","title":"Esomeprazole/Vonoprazan Combined With High-dose Amoxicillin Dual Therapy for Primary Eradication of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2024-02-10","conditions":"Helicobacter Pylori Infection","enrollment":806},{"nctId":"NCT04655157","phase":"PHASE1, PHASE2","title":"Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma","status":"TERMINATED","sponsor":"Jason J. Luke, MD","startDate":"2021-05-28","conditions":"Melanoma","enrollment":2},{"nctId":"NCT04462133","phase":"NA","title":"Optimal Tailored Treatment for H. Pylori Infection","status":"WITHDRAWN","sponsor":"Incheon St.Mary's Hospital","startDate":"2020-09-01","conditions":"Helicobacter Pylori Infection, Antibiotic Resistant Infection","enrollment":""},{"nctId":"NCT04147065","phase":"PHASE4","title":"Helicobacter Pylori Eradication According to DPO-PCR Methods (K-CREATE) Study)","status":"RECRUITING","sponsor":"Incheon St.Mary's Hospital","startDate":"2021-07-14","conditions":"Helicobacter Pylori Infection","enrollment":1230},{"nctId":"NCT06153875","phase":"NA","title":"Effects of Percutaneous Peripheral Nerve Stimulation on Neck and Low Back Pain","status":"COMPLETED","sponsor":"Clinica Francisco Ortega Rehabilitacion Avanzada SL","startDate":"2023-12-22","conditions":"Neck Pain, Low Back Pain","enrollment":45},{"nctId":"NCT05664685","phase":"PHASE4","title":"Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-10-17","conditions":"Helicobacter Pylori Infection","enrollment":127},{"nctId":"NCT06351891","phase":"PHASE4","title":"Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-04","conditions":"Helicobacter Pylori Infection","enrollment":248},{"nctId":"NCT05431075","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses","status":"COMPLETED","sponsor":"Shandong University","startDate":"2022-07-01","conditions":"Helicobacter Pylori Infection","enrollment":406},{"nctId":"NCT06315478","phase":"PHASE4","title":"Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-02-01","conditions":"H.Pylori Infection","enrollment":60},{"nctId":"NCT06275204","phase":"","title":"H. Pylori Screen-and-treat Study in a Population of Young Adults","status":"RECRUITING","sponsor":"University of Latvia","startDate":"2024-03-04","conditions":"Gastric Cancer, H Pylori Infection, H Pylori Eradication","enrollment":6800},{"nctId":"NCT06273280","phase":"NA","title":"Renal-based Optimization of QUADruple Therapy in Patients With Heart Failure With Reduced Ejection Fraction.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2024-02-14","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":345},{"nctId":"NCT05232981","phase":"NA","title":"Conservative Treatment of PAS With or Without IIL","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-05-01","conditions":"Placenta Accreta, Cesarean Hysterectomy, Pelvic Devascularization","enrollment":90},{"nctId":"NCT06216639","phase":"","title":"Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection","status":"UNKNOWN","sponsor":"National Institute of Public Health, Slovenia","startDate":"2024-02-01","conditions":"Helicobacter Pylori Infection","enrollment":2000},{"nctId":"NCT05997433","phase":"NA","title":"Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2023-09-02","conditions":"Helicobacter Pylori Infection","enrollment":254},{"nctId":"NCT05577468","phase":"PHASE3","title":"Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2022-10-30","conditions":"Helicobacter Pylori Infection","enrollment":561},{"nctId":"NCT05549115","phase":"NA","title":"Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Liaocheng People's Hospital","startDate":"2022-09-20","conditions":"Helicobacter Pylori Infection","enrollment":500},{"nctId":"NCT06143124","phase":"PHASE4","title":"Bismuth Quadruple Therapy Versus Standard Triple Therapy","status":"UNKNOWN","sponsor":"University Medical Centre Ljubljana","startDate":"2022-03-03","conditions":"Helicobacter Pylori Infection","enrollment":216},{"nctId":"NCT02547025","phase":"NA","title":"Personalized Treatment for Refractory H Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2012-08-01","conditions":"Helicobacter Pylori Infection","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1622,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Moxiflox, Downoprazol, Nanazoxid, Doxymycin","Esomeprazole (Nexium) 20mg bid","Metronidazole (Flagyl) 400mg qid","Bismuth subcitrate 120mg qid","Tetracycline 500mg qid"],"phase":"marketed","status":"active","brandName":"Quadruple therapy","genericName":"Quadruple therapy","companyName":"Sherief Abd-Elsalam","companyId":"sherief-abd-elsalam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Quadruple therapy combines four antiviral agents to simultaneously target multiple stages of viral replication and host factors. Used for Chronic hepatitis C virus (HCV) infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}